Evidence map›Paper›PMID 34678650›Full record

ArticleBiomaterials2021

Drug-eluting immune checkpoint blockade antibody-nanoparticle conjugate enhances locoregional and systemic combination cancer immunotherapy through T lymphocyte targeting.

David M Francis, Margaret P Manspeaker, Paul A Archer, Lauren F Sestito, Alexander J Heiler, Alex Schudel, Susan N Thomas

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Research progress on novel antibody drug conjugates in cancer therapy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024
    Review
  10. Review
  11. Review
  12. Elicitation of stem-like CD8Journal for immunotherapy of cancer · 2022
    Article
  13. Review
  14. Review
  15. Review
  16. Nanodrugs Targeting T Cells in Tumor Therapy.Frontiers in immunology · 2022
    Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

David M FrancisParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Margaret P ManspeakerParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Paul A ArcherParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Lauren F SestitoWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA.
Alexander J HeilerParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Alex SchudelParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA; School of Material Science and Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA.
Susan N ThomasParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, GA, 30332, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, 30332, USA; Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, GA, 30332, USA. Electronic address: susan.thomas@gatech.edu.
Georgia Institute of Technology · US

Funding

Lymph node-targeted multistage chemoimmunotherapy for lymphomaR01CA247484 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI FINN, M.G., THOMAS, SUSAN NAPIER · 2020 to 2024
$2.6M
Graduate Training for Rationally Designed, Integrative Biomaterials - GT BioMATT32EB006343 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI TEMENOFF, JOHNNA S · 2008 to 2018
$2.2M
Melanoma immunotherapy targeting sentinel lymph nodesR01CA207619 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI THOMAS, SUSAN NAPIER · 2016 to 2020
$2.0M
T32 Research Training Program in ImmunoEngineeringT32EB021962 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI JULIA E BABENSEE · 2017 to 2026
$1.9M
IVIS Spectrum in vivo Imaging SystemS10OD016264 · OD · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2015 to 2015
$595k
Role of HIV-1 Tat in the activation of HERV-K and development of HIV-1-lymphomaF31CA150523 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GONZALEZ-HERNANDEZ, MARTA JEANNETTE · 2010 to 2011
$65k
NCI NIH HHS F31 CA150523NCI NIH HHS R01 CA207619NCI NIH HHS R01 CA247484NIBIB NIH HHS T32 EB006343NIBIB NIH HHS T32 EB021962NIH HHS S10 OD016264
6 · The paper itself

Abstract

Multiple small molecule immune modulators have been identified as synergistic with immune checkpoint blockade (ICB) in their effects on T lymphocytes, but are limited in their successful application to combination cancer immunotherapy due to their short in vivo retention and lack of affinity for T cells. We engineered an antibody-nanoparticle conjugate (ANC) platform consisting of 30 nm polymer nanoparticles that, due to their size and formulation, efficiently distribute after administration to lymph nodes, tissues highly enriched in lymphocytes that contribute to tumor control mediated by ICB. Displaying monoclonal antibodies against surface-expressed T cell markers, NP delivery in vivo to circulating and lymph node-resident lymphocytes was substantially enhanced, as was delivery of small molecules formulated into the NP by passive encapsulation. Using ICB monoclonal antibodies as both targeting moiety and signal-blocking therapeutic, ANCs improved the local and systemic anti-tumor effects of small molecule TGFβ receptor 1 inhibitor and an adenosine 2A antagonist when administered either locoregionally or systemically into the circulation in two syngeneic, aggressive tumor models, slowing tumor growth and prolonging animal survival. As these benefits were lost in the absence of ANC targeting, co-formulation strategies enabling the targeted co-delivery of multiple immunotherapeutics to T lymphocytes have high potential to improve ICB cancer immunotherapy by concurrent inhibition of non-redundant suppressive pathways.

Indexed as

NanoparticlesNeoplasmsPharmaceutical PreparationsAnimalsImmune Checkpoint InhibitorsImmunotherapyT-LymphocytesImmune Checkpoint InhibitorsPharmaceutical PreparationsControlled releaseLymph nodeTargeted drug deliveryTumor immunotherapy

Identifiers

PMID34678650
PMCPMC8639654
OpenAlexW3206644945

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.